The Column Group
SEC exempt reporting adviser (venture capital exemption).
- HQ
- CA
The Column Group is a venture ecosystem focused on fueling scientific innovation in the life sciences. Peter Svennilson founded the firm in 2007 and serves as Founder and Managing Partner. Venture Partners Jeff Goater (joined 2021) and Craig Parker (joined 2024) also work with the firm. Its portfolio includes Sentrin Therapeutics, Topo, Synthekine, Atavistik Bio, Eikon Therapeutics, Peloton Therapeutics, and TriGemX Bio, spanning oncology, immune system therapies, hematology, and migraine treatment.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Series B, Series A, Growth |
| Sectors | Biotech | Not enough dated deals | Biotech, Healthtech, Life sciences and research tools, Medical devices |
| Regions | Not stated | Not enough dated deals | CA, MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2008 | 1 | Biotech, Healthtech |
| 2009 | 6 | Biotech, Healthtech, Life sciences and research tools |
| 2010 | 5 | Biotech, Healthtech, Life sciences and research tools |
| 2011 | 4 | Biotech, Healthtech, Medical devices |
| 2012 | 4 | Biotech, Healthtech, Life sciences and research tools |
| 2013 | 2 | Biotech, Healthtech, Medical devices |
| 2014 | 4 | Biotech, Healthtech, Life sciences and research tools |
| 2015 | 9 | Biotech, Healthtech, Fintech |
| 2016 | 5 | Biotech, Healthtech, Life sciences and research tools |
| 2017 | 7 | Biotech, Healthtech, Fintech |
| 2018 | 9 | Biotech, Healthtech, Life sciences and research tools |
| 2019 | 9 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 4 | Biotech, Healthtech, Life sciences and research tools |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 0 | 1 | 4 | 0 |
| 2011 | 0 | 0 | 2 | 2 | 0 |
| 2012 | 0 | 1 | 0 | 0 | 2 |
| 2013 | 0 | 0 | 1 | 0 | 1 |
| 2014 | 0 | 0 | 1 | 2 | 1 |
| 2015 | 0 | 0 | 4 | 2 | 2 |
| 2016 | 0 | 0 | 2 | 2 | 1 |
| 2017 | 0 | 0 | 2 | 1 | 4 |
| 2018 | 0 | 0 | 2 | 4 | 2 |
| 2019 | 0 | 0 | 2 | 3 | 4 |
| 2020 | 0 | 0 | 0 | 2 | 1 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Column Group VI, LP The Column Group is a venture ecosystem funding life sciences innovation, from early technology platforms and single assets to later-stage programs, from inception through exit, with a focus on biotechnology company formation. Inferred from the firm's website | approx. 2025 | $600M (Form D) | Raising |
| Column Group-Neuro II, LP The Column Group is a venture ecosystem funding life sciences innovation, from early technology platforms and single assets to later-stage programs, from inception through exit, with a focus on biotechnology company formation. Inferred from the firm's website | 2024 | $100M (Form D) | Open, writing first checks |
| Column Group V, LP The Column Group is a venture ecosystem funding life sciences innovation, from early technology platforms and single assets to later-stage programs, from inception through exit, with a focus on biotechnology company formation. Inferred from the firm's website | 2022 | $600M (Form D) | Late investment period |
| Column Group-Neuro, LP | 2021 | $100M (Form D) | Follow-ons only |
03 · People across funds
- David Goeddel, Managing Member of the General Partner of the General Partner
Column Group V, LP (Named on Form D)
- David Goeddel, PHD, Managing Member of the General Partner of the General Partner
Column Group-Neuro, LP (Named on Form D)
- Peter Svennilson, Founder / Managing Partner
Column Group VI, LP (Named on Form D); Column Group-Neuro II, LP (Named on Form D); Column Group V, LP (Named on Form D); Column Group-Neuro, LP (Named on Form D)
- Tim Kutzkey, Managing Partner
Column Group VI, LP (Named on Form D); Column Group-Neuro II, LP (Named on Form D); Column Group V, LP (Named on Form D)
- Tim Kutzkey, PHD, Managing Member of the General Partner of the General Partner
Column Group-Neuro, LP (Named on Form D)
- Craig Parker, Venture Partner
Column Group VI, LP (Team); Column Group-Neuro II, LP (Team); Column Group V, LP (Team); Column Group-Neuro, LP (Team)
- Jeff Goater, Venture Partner
Column Group VI, LP (Team); Column Group-Neuro II, LP (Team); Column Group V, LP (Team); Column Group-Neuro, LP (Team)
- Hui Tian, Partner
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- HTTP://WWW.THECOLUMNGROUP.COM
- https://www.thecolumngroup.com/contact/
- https://www.thecolumngroup.com/tcg-team/
- https://www.thecolumngroup.com/portfolio/
- https://www.thecolumngroup.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026